What is the recommended dose and duration of valacyclovir (Valtrex) for the treatment of genital herpes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Valacyclovir Dosing for Genital Herpes

Initial Episode

For the first episode of genital herpes, treat with valacyclovir 1 gram twice daily for 10 days, starting within 48 hours of symptom onset for maximum effectiveness. 1

Recurrent Episodes

For recurrent genital herpes outbreaks, use valacyclovir 500 mg twice daily for 3 days, initiated at the first sign or symptom of an episode. 1

  • This shorter 3-day course is sufficient for recurrent episodes, unlike the 10-day course needed for initial infection 1
  • Treatment should begin immediately when prodromal symptoms appear (tingling, itching, burning) 1
  • Alternative dosing of 1000 mg twice daily for 5 days has also shown efficacy in clinical trials 2

Suppressive Therapy (Chronic Prevention)

For Immunocompetent Patients

The standard suppressive dose is 1 gram once daily for patients with normal immune function. 1

  • For patients with ≤9 recurrences per year, 500 mg once daily is an acceptable alternative 1, 3
  • However, 500 mg once daily is less effective in patients with ≥10 recurrences per year, who should receive 1000 mg once daily 3, 4
  • Suppressive therapy reduces recurrence frequency by ≥75% 3, 5
  • Safety and efficacy documented for up to 1 year with valacyclovir 3

For HIV-Infected Patients

HIV-infected patients with CD4+ count ≥100 cells/mm³ require 500 mg twice daily (not once daily) for suppressive therapy. 1, 3, 6

  • The twice-daily dosing is critical in this population due to potentially more severe and frequent recurrences 3
  • This regimen has been shown to be as effective as acyclovir 400 mg twice daily in HIV-infected patients 6

Transmission Reduction

For reducing transmission to an uninfected partner, the source partner should take 500 mg once daily (for those with ≤9 recurrences per year). 1

Duration Considerations

  • After 1 year of continuous suppressive therapy, consider discontinuing to reassess recurrence frequency, as recurrences often decrease over time 3, 5
  • No laboratory monitoring is needed unless substantial renal impairment exists 3, 5

Important Clinical Caveats

  • Valacyclovir can be taken without regard to meals 1
  • Suppressive therapy reduces but does not eliminate asymptomatic viral shedding, so transmission risk remains 3, 5
  • If lesions persist beyond 7-10 days despite appropriate treatment, suspect HSV resistance—all acyclovir-resistant strains are also valacyclovir-resistant, requiring IV foscarnet instead 3
  • Avoid 8 grams per day dosing in immunocompromised patients due to risk of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome 3, 7
  • For patients with CrCl 30-49 mL/min, no dose reduction is needed, but lower creatinine clearance requires adjustment 3

References

Research

[Valaciclovir].

Annales de dermatologie et de venereologie, 2002

Guideline

Suppressive Therapy for Herpes Simplex Virus

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Timing of Maximal Effect for Suppressive Therapy in Oral HSV-1

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.